...
首页> 外文期刊>Biochemistry >Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
【24h】

Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.

机译:三价凝血酶抑制剂的P1'和P3'残基的设计及其晶体结构。

获取原文
获取原文并翻译 | 示例
           

摘要

Synthetic bivalent thrombin inhibitors comprise an active site blocking segment, a fibrinogen recognition exosite blocking segment, and a linker connecting these segments. Possible nonpolar interactions of the P1' and P3' residues of the linker with thrombin S1' and S3' subsites, respectively, were identified using the "Methyl Scan" method [Slon-Usakiewicz et al. (1997) Biochemistry 36, 13494-13502]. A series of inhibitors (4-tert-butylbenzenesulfonyl)-Arg-(D-pipecolic acid)-Xaa-Gly-Yaa-Gly-betaAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala- (be ta-cyclohexylalanine)-(D-Glu)-OH, in which nonpolar P1' residue Xaa or P3' residue Yaa was incorporated, were designed and improved the affinity to thrombin. Substitution of the P3' residue with D-phenylglycine or D-Phe improved the K(i) value to (9.5 +/- 0.6) x 10(-14) or 1.3 +/- 0.5 x 10(-13) M, respectively, compared to that of a reference inhibitor with Gly residues at Xaa and Yaa residues (K(i) = (2.4 +/- 0.5) x 10(-11) M). Similarly, substitution of the P1' residue with L-norleucine or L-beta-(2-thienyl)alanine lowered the K(i) values to (8.2 +/- 0.6) x 10(-14) or (5.1 +/- 0.4) x 10(-14) M, respectively. The linker Gly-Gly-Gly-betaAla of the inhibitors in the previous sentence was simplified with 12-aminododecanoic acid, resulting in further improvement of the K(i) values to (3.8 +/- 0.6) x 10(-14) or (1.7 +/- 0.4) x 10(-14) M, respectively. These K(i) values are equivalent to that of natural hirudin (2.2 x 10(-14) M), yet the size of the synthetic inhibitors (2 kD) is only one-third that of hirudin (7 kD). Two inhibitors, with L-norleucine or L-beta-(2-thienyl)alanine at the P1' residue and the improved linker of 12-aminododecanoic acid, were crystallized in complex with human alpha-thrombin. The crystal structures of these complexes were solved and refined to 2.1 A resolution. The Lys(60F) side chain of thrombin moved significantly and formed a large nonpolar S1' subsite to accommodate the bulky P1' residue.
机译:合成的二价凝血酶抑制剂包括一个活性位点封闭段,一个纤维蛋白原识别外位封闭段和一个连接这些段的接头。接头的P1'和P3'残基分别与凝血酶S1'和S3'亚位点的可能的非极性相互作用,是使用“甲基扫描”方法[Slon-Usakiewicz et al。 (1997)Biochemistry 36,13494-13502]。一系列抑制剂(4-叔丁基苯磺酰基)-Arg-(D-哌酸)-Xaa-Gly-Yaa-Gly-βAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(设计了其中掺入了非极性P1'残基Xaa或P3'残基Yaa的ta-环己基丙氨酸)-(D-Glu)-OH,并改善了对凝血酶的亲和力。用D-苯基甘氨酸或D-Phe取代P3'残基可将K(i)值分别提高到(9.5 +/- 0.6)x 10(-14)或1.3 +/- 0.5 x 10(-13)M ,与在Xaa和Yaa残基上具有Gly残基的参考抑制剂(K(i)=(2.4 +/- 0.5)x 10(-11)M)相比。同样,用L-正亮氨酸或L-β-(2-噻吩基)丙氨酸取代P1'残基会使K(i)值降低至(8.2 +/- 0.6)x 10(-14)或(5.1 +/-) 0.4)x 10(-14)M。上一句话中抑制剂的连接子Gly-Gly-Gly-βAla用12-氨基十二烷酸简化了,从而使K(i)值进一步提高到(3.8 +/- 0.6)x 10(-14)或(1.7 +/- 0.4)x 10(-14)M。这些K(i)值等于天然水rud素(2.2 x 10(-14)M),但合成抑制剂(2 kD)的大小仅为水only素(7 kD)的三分之一。与人α-凝血酶复合结晶了两种抑制剂,它们在P1'残基处具有L-正亮氨酸或L-β-(2-噻吩基)丙氨酸和改善的12-氨基十二烷酸接头。解决了这些络合物的晶体结构,并将其提纯至2.1 A分辨率。凝血酶的Lys(60F)侧链显着移动并形成一个大的非极性S1'亚位点,以容纳庞大的P1'残基。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号